# Aspirin in Colorectal Cancer Liver Metastases

Source: https://onco.cc/trials/nct03326791/  
OnCo record `nct03326791` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of aspirin in colorectal cancer, run by Oslo University Hospital, active but no longer recruiting.

## Summary

Aspirin in Colorectal Cancer Liver Metastases is a phase 2/3, randomised interventional study registered as NCT03326791 by Oslo University Hospital, with a registry enrolment figure of 466 participants, started 2017-12-15 and due to reach its primary completion in 2022-02-01. Interventions recorded: Acetylsalicylic acid; Placebo Oral Tablet. Conditions listed: Colorectal Cancer Liver Metastases; Colorectal Cancer; Liver Metastases. Primary outcome: Disease Free Survival (DFS) after three years treatment. Sites: Denmark, Norway, Sweden. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-24
- Also known as: ASAC
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT03326791
- Phase: 2/3
- Setting: Acetylsalicylic Acid as Secondary Prevention in Colorectal Cancer
- Sponsor: Oslo University Hospital
- Enrolled: 466

## Sources

- ClinicalTrials.gov NCT03326791: https://clinicaltrials.gov/study/NCT03326791

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- drugs: [Aspirin](https://onco.cc/drugs/aspirin/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct03326791.json